Drug
Fludarabine clinical trials
Also written Fluradosa.
Includes 259 studies of Fludarabine phosphate.
- studies test it
- 769
- open now
- 148
- in phase 3
- 50
- first study started
- 1994
Keep track of what changes. Save the fludarabine studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Brand
Development codes
Other names
Studies by the year they started
761 studies that test it; most in 2005 (37); 5 more planned to start later
| Year | Studies |
|---|---|
| 1994 | 1 |
| 1995 | 3 |
| 1996 | 2 |
| 1997 | 4 |
| 1998 | 14 |
| 1999 | 16 |
| 2000 | 18 |
| 2001 | 25 |
| 2002 | 30 |
| 2003 | 30 |
| 2004 | 30 |
| 2005 | 37 |
| 2006 | 31 |
| 2007 | 31 |
| 2008 | 26 |
| 2009 | 26 |
| 2010 | 27 |
| 2011 | 22 |
| 2012 | 23 |
| 2013 | 17 |
| 2014 | 27 |
| 2015 | 20 |
| 2016 | 26 |
| 2017 | 35 |
| 2018 | 28 |
| 2019 | 20 |
| 2020 | 29 |
| 2021 | 24 |
| 2022 | 20 |
| 2023 | 33 |
| 2024 | 19 |
| 2025 | 34 |
| 2026 | 33 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 31
- Phase 1
- 290
- Phase 2
- 457
- Phase 3
- 50
- Phase 4
- 13
- No phase
- 49
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 66 · Other 703
M.D. Anderson Cancer Center (73) · Fred Hutchinson Cancer Center (68) · National Cancer Institute (NCI) (44) · Masonic Cancer Center, University of Minnesota (28) · City of Hope Medical Center (20) · Memorial Sloan Kettering Cancer Center (20) · St. Jude Children's Research Hospital (19) · Baylor College of Medicine (17)
Often tested with
Tested in the same studies.
Cyclophosphamide (405) · Busulfan (149) · Melphalan (110) · Mycophenolic Acid (93) · Rituximab (91) · Tacrolimus (76) · Filgrastim (55) · Antilymphocyte Serum (54)
Studies
Open first, then newest update. How each study uses fludarabine is read from its arms, and is right about nine times in ten.
Testing it · 769
- Stem Cell Transplantation for Participants With Germline RUNX1 Associated Blood CancersNot yet recruitingPhase 2National Cancer Institute (NCI)NCT07524530Written as Fludarabine
- Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic MalignanciesRecruitingPhase 1National Cancer Institute (NCI)NCT06904066Written as fludarabine phosphate
- MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)RecruitingPhase 2National Cancer Institute (NCI)NCT05564390Written as Fludarabine
- Venetoclax or Placebo in Combination With Reduced-Intensity Conditioning Hematopoietic Cell (Bone Marrow/Blood Stem Cell) Transplant and as Maintenance Therapy After Transplant in Patients With Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)Not yet recruitingPhase 2National Cancer Institute (NCI)NCT06954987Written as Fludarabine
- Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)RecruitingPhase 2Fred Hutchinson Cancer CenterNCT03970096Written as Fludarabine
- T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung CancerRecruitingPhase 2National Cancer Institute (NCI)NCT02133196Written as Fludarabine
- T Cell Receptor T Cells for Advanced KRAS G12V-mutant Non-small Cell Lung Cancer, Pancreas Cancer, Colon CancerRecruitingPhase 1Fred Hutchinson Cancer CenterNCT06043713Written as Fludarabine
- Induction and Consolidation With Fludarabine, Cytarabine, Idarubicin, and Venetoclax for the Treatment of Acute Myeloid LeukemiaRecruitingPhase 2OHSU Knight Cancer InstituteNCT07228273Written as Fludarabine
- GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Solid Tumor MalignanciesRecruitingPhase 1National Cancer Institute (NCI)NCT05003895Written as Fludarabine
- Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing CancersRecruitingPhase 1/2National Cancer Institute (NCI)NCT02830724Written as Fludarabine
- Allogeneic Hematopoietic Stem Cell Transplant for GATA2 MutationsRecruitingPhase 2National Cancer Institute (NCI)NCT01861106Written as Fludarabine (Fludara, Berlex Laboratories)
- FGFR4 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory RhabdomyosarcomaRecruitingPhase 1National Cancer Institute (NCI)NCT06865664Written as fludarabine
- Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell LymphomaRecruitingPhase 2SWOG Cancer Research NetworkNCT05633615Written as Fludarabine
- CAR T-cell Therapy in Patients With Renal DysfunctionRecruitingPhase 2Northside Hospital, Inc.NCT05909059Written as Fludarabine
- HS-IT101 Injection for Advanced NSCLC(FASTIL-Lung01)RecruitingPhase 1Hangzhou Huasai Biomedicine Co., Ltd.NCT07105176Written as Fludarabine
- A Clinical Study of HS-IT101 Injection in Patients With Advanced Non-Small Cell Lung Cancer(FASTIL-Lung02)RecruitingPhase 1Hangzhou Huasai Biomedicine Co., Ltd.NCT07830342Written as Fludarabine
- CD34+ Enriched Transplants to Treat Myelodysplastic SyndromeNot yet recruitingNot applicableGuenther KoehneNCT05617625Written as Fludarabine
- CD34+ Transplants for Myeloid MalignanciesNot yet recruitingPhase 2Guenther KoehneNCT05565105Written as Fludarabine
- GPC2-CAR T Cell Therapy for Relapsed or Refractory Medulloblastoma in Children and Young AdultsRecruitingPhase 1Stanford UniversityNCT07087002Written as Fludarabine
- Total Marrow and Lymphoid Irradiation in Combination With Fludarabine and Melphalan as Conditioning for Allogeneic Peripheral Blood Stem Cell Hematopoietic Cell Transplant in Older Patients With Refractory and Relapsed Acute Myeloid Leukemia and High-risk Myelodysplastic SyndromeRecruitingPhase 2City of Hope Medical CenterNCT07582172Written as Fludarabine Phosphate
See all 769 studies that test fludarabine →
Given in every arm · 724 — fludarabine is usual care beside what is tested
- Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic CancerRecruitingPhase 2National Cancer Institute (NCI)NCT01174121Written as Fludarabine
- Anti-CRLF2-R/TSLPR Chimeric Antigen Receptor T Cells (TSLPR-CART) in Participants With Recurrent or Refractory CRLF2-R/TSLPR-Overexpressing B-Cell Acute Lymphoblastic Leukemia (B-ALL)RecruitingPhase 1National Cancer Institute (NCI)NCT07572136Written as Fludarabine
- IL-12 Genetically Engineered Myeloid Cells in Participants With Relapsed, Refractory Solid TumorsRecruitingPhase 1National Cancer Institute (NCI)NCT07672483Written as Fludarabine
- Natalizumab for the Prevention of ICANS in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma Receiving CAR T-Cell TherapyRecruitingPhase 2University of Michigan Rogel Cancer CenterNCT07892027Written as Fludarabine
- Study of Anitocabtagene Autoleucel in Participants With Non-Oncology Plasma Cell-Related DiseasesRecruitingPhase 1Kite, A Gilead CompanyNCT06626919Written as Fludarabine
- CD22 CAR T-cells to Extend Remission Following Commercial CD19 CAR T-cells in Children, Adolescents, and Adults With Relapsed/Refractory B-cell Acute Lymphoblastic LeukemiaRecruitingPhase 2National Cancer Institute (NCI)NCT07328503Written as Fludarabine
- A Trial to Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Standard of Care in Newly Diagnosed Multiple MyelomaNot yet recruitingPhase 3Kite, A Gilead CompanyNCT07887672Written as Fludarabine
- CER-1236 in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis (MF)RecruitingPhase 1CERo Therapeutics Holdings, Inc.NCT06834282Written as Fludarabine
- A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).RecruitingPhase 3AstraZenecaNCT07735637Written as Fludarabine
- Autologous B7-H3 Chimeric Antigen Receptor T Cells in Previously Treated Extensive-Stage Small Cell Lung Cancer With Recurrent or Refractory DiseaseRecruitingPhase 1National Cancer Institute (NCI)NCT07509034Written as Fludarabine
- Allogeneic Hematopoietic Stem Cell Transplant for Patients With Inborn Errors of ImmunityRecruitingPhase 2National Cancer Institute (NCI)NCT04339777Written as Fludarabine
- Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap SyndromesRecruitingPhase 2Fred Hutchinson Cancer CenterNCT07228624Written as Fludarabine
- Study of KITE-363 in Participants With Autoimmune Neurologic Diseases That Did Not Respond to Usual TreatmentRecruitingPhase 1Kite, A Gilead CompanyNCT07304154Written as Fludarabine
- Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic MalignanciesRecruitingPhase 1/2National Cancer Institute (NCI)NCT05327023Written as Fludarabine
- Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for LeukemiasRecruitingPhase 1/2National Cancer Institute (NCI)NCT06364423Written as Fludarabine
- The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell TransplantationRecruitingPhase 1/2National Cancer Institute (NCI)NCT05436418Written as Fludarabine
- Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic MalignanciesRecruitingPhase 1/2National Cancer Institute (NCI)NCT04959175Written as Fludarabine
- Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including MesotheliomaRecruitingPhase 1National Cancer Institute (NCI)NCT06885697Written as fludarabine
- Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic CancerRecruitingPhase 2National Cancer Institute (NCI)NCT03412877Written as Fludarabine
- A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for Subjects With VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic) SyndromeRecruitingPhase 2National Cancer Institute (NCI)NCT05027945Written as Fludarabine
Showing 20 of 724.
As the comparator · 25 — what is tested is compared with fludarabine
- Bendamustine Versus Fludarabine/Cyclophosphamide for Lymphodepletion in Chimeric Antigen Receptor T-cell Immunotherapy (CAR-T): a Randomized Trial.RecruitingPhase 2Swiss Cancer InstituteNCT07593482Written as Fludarabine
- A Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL.RecruitingPhase 3Ascentage Pharma Group Inc.NCT06319456Written as Fludarabine
- Fludarabine Plus Melphalan Versus Addition of Venetoclax to Fludarabine/Melphalan Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in AML/MDS Patients Aged > 50 Years: a Multicenter, Randomized, Phase 3 TrialRecruitingPhase 3First Affiliated Hospital of Zhejiang UniversityNCT07396480Written as Fludarabine and Melphalan
- Study Comparing the Efficacy of 2 RIC Regimens (Clofarabine vs Fludarabine) in Adults With AML Eligible to Allo-SCTRecruitingPhase 2Nantes University HospitalNCT05917405Written as Fludarabine
- A Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase 3 (FLT3) MutationCompletedPhase 3Astellas Pharma IncNCT03182244Written as Fludarabine
- Haplocompatible Transplant Using TCRα/β Depletion Followed by CD45RA-Depleted Donor Lymphocyte Infusions for Severe Combined Immunodeficiency (SCID)Active, not recruitingPhase 1/2St. Jude Children's Research HospitalNCT03597594Written as Fludarabine
- Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaActive, not recruitingPhase 3National Cancer Institute (NCI)NCT02048813Written as Fludarabine Phosphate
- A Comparison of Reduced Dose Total Body Irradiation (TBI) and Cyclophosphamide With Fludarabine and Melphalan Reduced Intensity Conditioning in Adults With Acute Lymphoblastic Leukaemia (ALL) in Complete Remission. (ALL-RIC)Active, not recruitingPhase 2University of BirminghamNCT03821610Written as Fludarabine
- A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)Active, not recruitingPhase 3Merck Sharp & Dohme LLCNCT05624554Written as Fludarabine
- A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 MutationCompletedPhase 3Hoffmann-La RocheNCT04285567Written as Fludarabine
- Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th SalvageTerminatedPhase 3Delta-Fly Pharma, Inc.NCT03926624Written as Fludarabine
- Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified TreatmentCompletedPhase 3Goethe UniversityNCT02881086Written as Fludarabine
- Standard Chemoimmunotherapy (FCR/BR) Versus Rituximab + Venetoclax (RVe) Versus Obinutuzumab (GA101) + Venetoclax (GVe) Versus Obinutuzumab + Ibrutinib + Venetoclax (GIVe) in Fit Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without Del(17p) or TP53 MutationCompletedPhase 3German CLL Study GroupNCT02950051Written as Fludarabine
- Bendamustine Plus Rituximab Versus Fludarabine Plus RituximabCompletedPhase 3University of GiessenNCT01456351Written as Fludarabine 25 mg/m² d 1-3 + Rituximab 375 mg/m² d 1 q4w
- Efficacy/Safety of CPI-613 in Combination With HD Cyt. and Mito. vs HD Cyt. and Mito. in Older Patients With R/R AMLTerminatedPhase 3Cornerstone PharmaceuticalsNCT03504410Written as Fludarabine, Cytarabine, Filgrastim
- Cladribine Combined With G-CSF and Cytarabine as a Salvage Treatment in R/R ALLStatus unknownPhase 2/3The First Affiliated Hospital of Soochow UniversityNCT05578378Written as Fludarabine
- CBA Versus FBA Conditioning Followed by Haploidentical Allogeneic HSCT in Treatment of High Risk and Refractory AMLStatus unknownPhase 3Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineNCT03384225Written as Fludarabine
- CBA Versus FBA Conditioning Followed by Allogeneic HSCT in Treatment of High Risk and Refractory AMLStatus unknownPhase 3Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineNCT03384212Written as Fludarabine
- Randomised Trial in Waldenstrom's MacroglobulinaemiaCompletedPhase 2University College, LondonNCT01592981Written as Fludarabine
- Azacytidine (Vidaza®) Versus Fludarabine and Cytarabine (Fluga Scheme) in Elderly Patients With Newly Diagnosed Acute Myeloid LeukemiaCompletedPhase 3PETHEMA FoundationNCT02319135Written as Fludarabine
Showing 20 of 25.
Codes
What other systems call fludarabine · ClinicalTrials.gg INT002787
- MeSH (NLM) C024352fludarabineConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) P2K93U8740FLUDARABINEConfirmed FDA, NLM, Wikidata
- RxNorm 24698Confirmed FDA, Wikidata
- Wikidata Q72478349fludarabineConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C1094FludarabineOne source FDA
- DrugBank DB01073One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C024352 | fludarabine | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | P2K93U8740 | FLUDARABINE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 24698 | — | Confirmed FDA, Wikidata |
| Wikidata | Q72478349 | fludarabine | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C1094 | Fludarabine | One source FDA |
| DrugBank | DB01073 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.